Quest Diagnostics shares rose 3.1% this morning to a price of $140.9. The stock is still trading within range of its average target price of $147.46, and over the last 52 weeks, it has recorded a 1.4% performance. Analysts have given the Large-Cap Medical Specialities stock target prices ranging from $136.0 to $160.0 dollars per share, with an average rating of buy.
Quest Diagnostics's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.4%. The stock's short ratio is 2.75. The company's insiders own 0.44% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 92.9%. In conclusion, we believe there is mixed market sentiment regarding Quest Diagnostics.
Institutions Invested in Quest Diagnostics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 13% | 13,921,955 | $1,961,603,374 |
| 2024-03-31 | Blackrock Inc. | 10% | 10,700,573 | $1,507,710,670 |
| 2024-03-31 | State Street Corporation | 5% | 5,199,194 | $732,566,402 |
| 2024-03-31 | Victory Capital Management Inc. | 4% | 3,922,331 | $552,656,413 |
| 2024-03-31 | American Century Companies Inc | 3% | 3,873,742 | $545,810,224 |
| 2024-03-31 | Wellington Management Group, LLP | 2% | 2,612,769 | $368,139,136 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 2,533,572 | $356,980,279 |
| 2024-03-31 | Davis Selected Advisers, LP | 2% | 2,381,163 | $335,505,852 |
| 2024-03-31 | Grantham, Mayo, Van Otterloo & Co. LLC | 2% | 2,043,255 | $287,894,617 |
| 2024-03-31 | Dimensional Fund Advisors LP | 2% | 1,980,120 | $278,998,895 |
